On October 19, 2026, the first three patients with congenital erythropoietic porphyria (CEP) enrolled in the ATL001-PII-CEP clinical trial received their first dose of ATL-001, Atlas Molecular ...
MIAMI, Oct. 20, 2026 -- Ocubio, a Miami-based biotechnology company developing regenerative ophthalmic solutions, today ...
Parse Biosciences, the leading provider of scalable and accessible single cell sequencing and a QIAGEN company, today ...
Favorable interim safety and tolerability profile observed across single and multiple ascending dose cohorts in healthy ...
Rapport Therapeutics clocked its second Phase 2 win in 14 months for RAP-219—which the company is positioning as a potential ...
The Company remains on track to complete 12-month visits by early Q2 2027. Envoy Medical has submitted two of the four ...
Sarah Cannon Research Institute (SCRI), one of the world’s leading oncology research organizations conducting community-based ...
GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced plans to enhance its genome testing portfolio with long-read whole ...
AbbVie (NYSE: ABBV), a global pharmaceutical leader, and McLaren Racing today announced a multi-year partnership naming ...
Designation follows recent IND activation and builds on Orphan Drug Designation granted in 2025. NEW YORK, Oct. 20, 2026 ...
In UC, duvakitug maintained high rates of clinical remission, clinical response, and endoscopic improvement at Week 44 In CD, ...
Parkinson’s patients elevated baseline inflammation demonstrated statistically significant improvements in both motor and non ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results